The Dana-Farber/Harvard Cancer Center (DF/HCC) is a cancer research consortium between seven Boston participating institutions, including:
- Beth Israel Deaconess Medical Center (BIDMC),
- Brigham and Women’s Hospital (BWH),
- Boston Children’s Hospital (BCH),
- Dana-Farber Cancer Institute (DFCI),
- Harvard Medical School (HMS),
- Harvard T.H. Chan School of Public Health, and
- Massachusetts General Hospital (MGH).
DF/HCC was formed in 1999 as a formal collaboration and is the powerful successor organization to the Dana-Farber Cancer Institute Comprehensive Cancer Center, one of the original cancer centers designated by the NCI in 1973.The cancer research and treatment collaborations sponsored across the participating institutions by the DF/HCC combines the disciplines of population science, clinical science, and basic research, to facilitate the development of novel and improved modalities for the prevention and treatment of cancer.
The population sciences programs and cores are linked below. Those for basic and clinical sciences can be reached via the general program and core links. Membership information can be found via the DF/HCC website link.